These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 30724094)
1. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal. Doughty B; Morgenson D; Brooks T Ann Pharmacother; 2019 Jul; 53(7):746-753. PubMed ID: 30724094 [TBL] [Abstract][Full Text] [Related]
2. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Gish EC; Miller JL; Honey BL; Johnson PN Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696 [TBL] [Abstract][Full Text] [Related]
3. Lofexidine (Lucemyra) for opioid withdrawal. Med Lett Drugs Ther; 2018 Jul; 60(1551):115-117. PubMed ID: 30036346 [No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial. Fishman M; Tirado C; Alam D; Gullo K; Clinch T; Gorodetzky CW; J Addict Med; 2019; 13(3):169-176. PubMed ID: 30531234 [TBL] [Abstract][Full Text] [Related]
5. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421 [TBL] [Abstract][Full Text] [Related]
6. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review. Kuszmaul AK; Palmer EC; Frederick EK J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720 [TBL] [Abstract][Full Text] [Related]
7. Buprenorphine for managing opioid withdrawal. Gowing L; Ali R; White JM; Mbewe D Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474 [TBL] [Abstract][Full Text] [Related]
8. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Sinha R; Kimmerling A; Doebrick C; Kosten TR Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399 [TBL] [Abstract][Full Text] [Related]
9. Opioid antagonists with minimal sedation for opioid withdrawal. Gowing L; Ali R; White JM Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701 [TBL] [Abstract][Full Text] [Related]
10. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009 [TBL] [Abstract][Full Text] [Related]
11. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Strang J; Bearn J; Gossop M Am J Addict; 1999; 8(4):337-48. PubMed ID: 10598217 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Walsh SL; Strain EC; Bigelow GE Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813 [TBL] [Abstract][Full Text] [Related]
13. Buprenorphine for the management of opioid withdrawal. Gowing L; Ali R; White JM Cochrane Database Syst Rev; 2009 Jul; (3):CD002025. PubMed ID: 19588330 [TBL] [Abstract][Full Text] [Related]
14. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals. Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527 [TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms. Urits I; Patel A; Zusman R; Virgen CG; Mousa M; Berger AA; Kassem H; Jung JW; Hasoon J; Kaye AD; Viswanath O Psychopharmacol Bull; 2020 Jul; 50(3):76-96. PubMed ID: 32733113 [TBL] [Abstract][Full Text] [Related]
17. FDA approves nonopioid medication for managing opioid withdrawal. Traynor K Am J Health Syst Pharm; 2018 Jul; 75(13):927. PubMed ID: 29941528 [No Abstract] [Full Text] [Related]
18. Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal. Darpö B; Pirner M; Longstreth J; Ferber G Drug Alcohol Depend; 2019 Dec; 205():107596. PubMed ID: 31606589 [TBL] [Abstract][Full Text] [Related]
19. Management of opioid withdrawal symptoms. Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420 [No Abstract] [Full Text] [Related]
20. Opioid antagonists with minimal sedation for opioid withdrawal. Gowing L; Ali R; White JM Cochrane Database Syst Rev; 2009 Oct; (4):CD002021. PubMed ID: 19821290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]